Early pregnancy exposure to selective serotonin reuptake inhibitors, risks of major structural malformations, and hypothesized teratogenic mechanisms

@article{Gentile2015EarlyPE,
  title={Early pregnancy exposure to selective serotonin reuptake inhibitors, risks of major structural malformations, and hypothesized teratogenic mechanisms},
  author={S. Gentile},
  journal={Expert Opinion on Drug Metabolism \& Toxicology},
  year={2015},
  volume={11},
  pages={1585 - 1597}
}
  • S. Gentile
  • Published 2015
  • Medicine
  • Expert Opinion on Drug Metabolism & Toxicology
Introduction: Selective serotonin reuptake inhibitors (SSRIs) are commonly used to manage antenatal depression. Hence, the aim of this systematic review is to assess the prevalence of birth defects associated with pregnancy exposure to such agents and summarize the hypothesized teratogenic mechanisms. Areas covered: Medical literature published in English (1980 – June 2015) was electronically searched to identify all articles reporting an increased prevalence of birth defects associated with… Expand
Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births
TLDR
The evidence suggests a generally small risk of congenital malformations and argues against a substantial teratogenic effect of SSRIs and Caution is advisable in making decisions about whether to continue or stop treatment withSSRIs during pregnancy. Expand
Maternal drug use and the risk of anorectal malformations: systematic review and meta-analysis
TLDR
Evidence on maternal drug use before conception and during pregnancy as risk factor for ARM from epidemiological studies is still very limited, and the few available studies indicate any anti-asthma medication, and hypnotics and benzodiazepine to be associated with increased risks. Expand
Fluoxetine and congenital malformations: a systematic review and meta‐analysis of cohort studies
TLDR
The results of this meta-analysis indicate maternal fluoxetine use is associated with a slightly increased risk of cardiovascular malformations in infants, and health care providers and pregnant women must weigh the risk-benefit potential of these drugs when making decisions about whether to treat with fluoxettine during pregnancy. Expand
Managing fibromyalgia syndrome in pregnancy no bridges between USA and EU
TLDR
The risk/benefit ratio of using psychotropic drugs approved in some countries for treating fibromyalgia syndrome (FMS) during pregnancy is analyzed and the effectiveness of non-pharmacological interventions is assessed to help clinicians to manage FMS in pregnancy in those countries were no drugs are approved for treating the disease. Expand
Antidepressant use in pregnancy and severe cardiac malformations: Danish register-based study.
TLDR
Pregnancy exposure to venlafaxine is associated with an increased risk of severe cardiac malformations but with a low absolute risk, and potential mechanisms include direct effects or confounding by indication. Expand
Developmental Fluoxetine Exposure Alters Behavior and Neuropeptide Receptors in the Prairie Vole
TLDR
Changes to oxytocin and vasopressin receptors may underlie the behavioral changes observed and have translational implications for the mechanism of the increased risk of ASD subsequent to prenatal SSRI exposure. Expand
Syddansk Universitet Perception of drug teratogenicity among general practitioners and specialists in obstetrics / gynecology a regional and national questionnaire-based survey
Background: Estimating the true risk of fetal malformations attributable to the use of medications is difficult and perception of risk by health professionals will impact their counseling andExpand
Perception of drug teratogenicity among general practitioners and specialists in obstetrics/gynecology: a regional and national questionnaire-based survey
TLDR
The risk associated with warfarin and retinoid exposure was severely underestimated by both groups of health care professionals, while general practitioners specifically overestimated the risk of sertraline and citalopram to some extent. Expand
Depression During Pregnancy and Postpartum
TLDR
The use of antidepressants during pregnancy and postpartum must be weighed against the risk of untreated depression in the mother, as well as a possible connection with autism spectrum disorder. Expand
The Pathways between Cortisol-Related Regulation Genes and PTSD Psychotherapy
TLDR
This review aims to address how knowledge of the HPA axis-related genetic makeup can inform and predict the outcomes of psychotherapeutic treatments. Expand
...
1
2
...

References

SHOWING 1-10 OF 103 REFERENCES
Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine.
TLDR
The teratogenic potential of paroxetine that has been reported in some studies remains unproven and this relevant safety question is likely to remain unanswered until large, prospective studies are conducted. Expand
Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study
TLDR
Risks of congenital malformations of the heart were similar for pregnancies exposed to an SSRI throughout the first trimester and for pregnancies with paused SSRI treatment during pregnancy, and the authors found no association with dosage. Expand
Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations.
TLDR
Use of SSRIs in early pregnancy does not seem to be a major risk factor for infant malformations, and the association between paroxetine use and infant cardiovascular defects may be a result of multiple testing, but is supported by other studies. Expand
Maternal Use of Selective Serotonin Reuptake Inhibitors and Risk of Congenital Malformations
TLDR
An increased risk of congenital malformations after exposure to SSRIs in early pregnancy is found, although it is unclear whether the effects were causal or due to factors related to the underlying disease. Expand
Sertraline use during pregnancy and the risk of major malformations.
TLDR
Sertraline use during the first trimester of pregnancy was associated with an increased risk of atrial/ventricular defects and craniosynostosis above and beyond the effect of maternal depression. Expand
Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects.
TLDR
Maternal use of SSRIs during early pregnancy was not associated with significantly increased risks of congenital heart defects or of most other categories of birth defects. Expand
Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study
TLDR
There is an increased prevalence of septal heart defects among children whose mothers were prescribed an SSRI in early pregnancy, particularly sertraline and citalopram, particularly in women who redeemed prescriptions for more than one type of SSRI. Expand
Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy.
TLDR
Data from a retrospective review of the medical records of all pregnant women presenting at Mayo Clinic's site in Rochester, MN, from January 1, 1993, to July 15, 2005 are reassuring regarding the safety of using SSRIs during pregnancy. Expand
Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis
TLDR
Findings suggest an association between maternal SSRI use in early pregnancy and cardiac malformations which could be causal, and for specific SSRIs, an increased risk for septal defects associated with sertraline. Expand
First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects.
TLDR
It is suggested that individual SSRIs may confer increased risks for some specific defects, but it should be recognized that the specific defects implicated are rare and the absolute risks are small. Expand
...
1
2
3
4
5
...